FDA To Allow Lower-Dose Trials For Merck’s HIV Drug islatravir

Merck has caught a lucky break with its HIV treatment solutions enterprise, as the FDA has cleared its drug islatravir of a nine-month clinical trial hold. The only condition of the release: low doses are used. Merck has also indicated it will no longer spend time exploring islatravir as a preventative treatment...